Pharmacometabolomic assessment of metformin in non-diabetic, African Americans

Daniel M. Rotroff, Noffisat O. Oki, Xiaomin Liang, Sook Wah Yee, Sophie L. Stocker, Daniel G. Corum, Michele Meisner, Oliver Fiehn, Alison A. Motsinger-Reif, Kathleen M. Giacomini, Rima Kaddurah-Daouk

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Millions of individuals are diagnosed with type 2 diabetes mellitus (T2D), which increases the risk for a plethora of adverse outcomes including cardiovascular events and kidney disease. Metformin is the most widely prescribed medication for the treatment of T2D; however, its mechanism is not fully understood and individuals vary in their response to this therapy. Here, we use a non-targeted, pharmacometabolomics approach to measure 384 metabolites in 33 non-diabetic, African American subjects dosed with metformin. Three plasma samples were obtained from each subject, one before and two after metformin administration. Validation studies were performed in wildtype mice given metformin. Fifty-four metabolites (including 21 unknowns) were significantly altered upon metformin administration, and 12 metabolites (including six unknowns) were significantly associated with metformin-induced change in glucose (q < 0.2). Of note, indole-3-acetate, a metabolite produced by gut microbes, and 4-hydroxyproline were modulated following metformin exposure in both humans and mice. 2-Hydroxybutanoic acid, a metabolite previously associated with insulin resistance and an early biomarker of T2D, was positively correlated with fasting glucose levels as well as glucose levels following oral glucose tolerance tests after metformin administration. Pathway analysis revealed that metformin administration was associated with changes in a number of metabolites in the urea cycle and in purine metabolic pathways (q < 0.01). Further research is needed to validate the biomarkers of metformin exposure and response identified in this study, and to understand the role of metformin in ammonia detoxification, protein degradation and purine metabolic pathways.

Original languageEnglish (US)
Article number135
JournalFrontiers in Pharmacology
Volume7
Issue numberJUN
DOIs
StatePublished - Jun 14 2016

Keywords

  • Metabolism
  • Metformin
  • Pharmacometabolomics
  • Precision medicine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'Pharmacometabolomic assessment of metformin in non-diabetic, African Americans'. Together they form a unique fingerprint.

  • Cite this

    Rotroff, D. M., Oki, N. O., Liang, X., Yee, S. W., Stocker, S. L., Corum, D. G., Meisner, M., Fiehn, O., Motsinger-Reif, A. A., Giacomini, K. M., & Kaddurah-Daouk, R. (2016). Pharmacometabolomic assessment of metformin in non-diabetic, African Americans. Frontiers in Pharmacology, 7(JUN), [135]. https://doi.org/10.3389/fphar.2016.00135